Write in a clean editor, then format for Breast Cancer Research in one click — DocuGuru applies the official BMC (BioMed Central) template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Breast Cancer Research is a peer-reviewed journal published by BMC (BioMed Central), covering Breast Cancer Treatment Studies, Cancer Cells and Metastasis, Breast Lesions and Carcinomas. Over its lifetime it has published 5,875 papers, which have received 257,800 citations.
| Publisher | BMC (BioMed Central) |
|---|---|
| Reference style | Numbered (Vancouver) Numbered — [1], [2] in the text 1. Smith A, Jones B, Lee C. A representative article title. Breast Cancer Research. 2023;12(3):45–58.
Formats any DOI in Breast Cancer Research style. No sign-up. |
| Publishes research in | Breast Cancer Treatment Studies Cancer Cells and Metastasis Breast Lesions and Carcinomas HER2/EGFR in Cancer Research Estrogen and related hormone effects |
| ISSN | 1465-5411 |
| Citation impact (2-yr) | 5.15 |
| h-index | 209 |
| i10-index | 3,096 |
| Article processing charge | $2,919 |
| Open access | Yes — indexed in DOAJ |
| Top institutions publishing here | Harvard University |
| Journal website | link.springer.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER-2), has clinical features that include high invasiveness, high metastatic potential, proneness to relapse, and poor prognosis. Because TNBC tumors lack ER, PR, and HER2 expression, they are…
INTRODUCTION: In breast cancer, gene expression analyses have defined five tumor subtypes (luminal A, luminal B, HER2-enriched, basal-like and claudin-low), each of which has unique biologic and prognostic features. Here, we comprehensively characterize the recently identified claudin-low tumor subtype. METHODS: The clinical, pathological and biological features of claudin-low tumors were compared to the other tumor…
Breast cancer is a complex and heterogeneous disease. Gene expression profiling has contributed significantly to our understanding of this heterogeneity at a molecular level, refining taxonomy based on simple measures such as histological type, tumour grade, lymph node status and the presence of predictive markers like oestrogen receptor and human epidermal growth factor receptor 2…
While advances in science and technology have increased options for treating breast cancer, current social trends have changed the way people deal with this disease.Women in the United States are no longer simply passive patients, but rather they are survivors, advocates and activists who are speaking up for themselves and speaking out for issues relevant…
INTRODUCTION: Alterations in cell cycle regulators have been implicated in human malignancies including breast cancer. PD 0332991 is an orally active, highly selective inhibitor of the cyclin D kinases (CDK)4 and CDK6 with ability to block retinoblastoma (Rb) phosphorylation in the low nanomolar range. To identify predictors of response, we determined the in vitro sensitivity…
